[Fullevir: in vitro and in vivo antiherpetic activity].
The antiherpetic properties of a fullerene derivative with aminocaproic acid (manufactured by Intelfarm Co. as Fullevir) were studied in in vitro (in sensitive cell cultures) and in vivo (on a murine model of experimental herpetic encephalitis) experiments. Fullevir was found to protect tissue culture cells from the cytodestructive action of herpes simplex virus type 1. It was estimated that ED50 = 5.3 microg/ml and ED90 = 29.1 microg/ml. The agent was most effective when it was administered before and 30 minutes after cell culture infection. The in vivo study established that Fullevir showed a significant protective effect in experimental herpetic encephalitis. The protection rates were 29.8% and 41.0% with the total doses of Fullevir of 500 mg/kg (p < 0.007) and 1000 mg/kg (p < 0.004), respectively. Thus, the in vitro and in vivo studies demonstrated the antiherpetic effect of a fullerene-aminocaproic acid complex (1-hydrofullereneaminocaproic acid, sodium salt) having the trade name Fullevir.
Nosik
N N
NN
Kondrashina
N G
NG
Grigor'eva
A Iu
AIu
Lialina
I K
IK
Rasnetsov
L D
LD
D000212:Acyclovir / Q000494:pharmacology; D000614:Aminocaproates / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002522:Chlorocebus aethiops; D003588:Cytopathogenic Effect, Viral / Q000187:drug effects; D004195:Disease Models, Animal; D020803:Encephalitis, Herpes Simplex / Q000821:virology; D037741:Fullerenes / Q000494:pharmacology* / Q000627:therapeutic use; D018259:Herpesvirus 1, Human / Q000187:drug effects*; D006801:Humans; D008297:Male; D051379:Mice; D014709:Vero Cells; D014779:Virus Replication / Q000187:drug effects
C540009:1-hydrofullereneaminocaproic acid, sodium salt; D000614:Aminocaproates; D000998:Antiviral Agents; D037741:Fullerenes; D000212:Acyclovir